RU2010138603A - Композиция для модуляции роста стволовых клеток простагландинами - Google Patents
Композиция для модуляции роста стволовых клеток простагландинами Download PDFInfo
- Publication number
- RU2010138603A RU2010138603A RU2010138603/15A RU2010138603A RU2010138603A RU 2010138603 A RU2010138603 A RU 2010138603A RU 2010138603/15 A RU2010138603/15 A RU 2010138603/15A RU 2010138603 A RU2010138603 A RU 2010138603A RU 2010138603 A RU2010138603 A RU 2010138603A
- Authority
- RU
- Russia
- Prior art keywords
- hydroxy
- alkyl
- cyclo
- halogen
- prostaglandin
- Prior art date
Links
- 150000003180 prostaglandins Chemical class 0.000 title claims abstract 22
- 210000000130 stem cell Anatomy 0.000 title claims 16
- 239000000203 mixture Substances 0.000 title claims 6
- 230000010261 cell growth Effects 0.000 title 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims abstract 56
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 48
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 42
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 35
- 229910052736 halogen Inorganic materials 0.000 claims abstract 28
- 150000002367 halogens Chemical class 0.000 claims abstract 28
- 125000004423 acyloxy group Chemical group 0.000 claims abstract 21
- 125000003118 aryl group Chemical group 0.000 claims abstract 21
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 21
- 239000001257 hydrogen Substances 0.000 claims abstract 21
- 150000002431 hydrogen Chemical class 0.000 claims abstract 21
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 14
- 125000001931 aliphatic group Chemical group 0.000 claims abstract 14
- 125000004104 aryloxy group Chemical group 0.000 claims abstract 14
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 14
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims abstract 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 7
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims abstract 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 7
- 229910052799 carbon Inorganic materials 0.000 claims abstract 7
- 150000001721 carbon Chemical group 0.000 claims abstract 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 7
- 230000004069 differentiation Effects 0.000 claims abstract 7
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 7
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 7
- 239000001301 oxygen Substances 0.000 claims abstract 7
- 230000035755 proliferation Effects 0.000 claims abstract 7
- 229910052717 sulfur Chemical group 0.000 claims abstract 7
- 239000011593 sulfur Chemical group 0.000 claims abstract 7
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims 2
- 150000000258 13,14-dihydro-15-keto-prostaglandin D2 derivatives Chemical class 0.000 claims 1
- CDUVSQMTLOYKTR-ZHALLVOQSA-N 13,14-dihydro-15-oxoprostaglandin E1 Chemical compound CCCCCC(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O CDUVSQMTLOYKTR-ZHALLVOQSA-N 0.000 claims 1
- PNVYHTHOCKTJCO-JOCBIADPSA-N 7-[(1r,2r,3r)-2-[(3r)-4,4-difluoro-3-hydroxyoctyl]-3-hydroxy-5-oxocyclopentyl]heptanoic acid Chemical compound CCCCC(F)(F)[C@H](O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O PNVYHTHOCKTJCO-JOCBIADPSA-N 0.000 claims 1
- 210000001671 embryonic stem cell Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000001988 somatic stem cell Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
- C07C53/134—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2971308P | 2008-02-19 | 2008-02-19 | |
| US61/029,713 | 2008-02-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010138603A true RU2010138603A (ru) | 2012-03-27 |
Family
ID=40602552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010138603/15A RU2010138603A (ru) | 2008-02-19 | 2009-02-19 | Композиция для модуляции роста стволовых клеток простагландинами |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8871752B2 (enExample) |
| EP (2) | EP2656845A1 (enExample) |
| JP (1) | JP2011512323A (enExample) |
| KR (1) | KR20100119803A (enExample) |
| CN (2) | CN102014921A (enExample) |
| AR (1) | AR073158A1 (enExample) |
| AU (1) | AU2009216067B2 (enExample) |
| BR (1) | BRPI0907831A2 (enExample) |
| CA (1) | CA2715486A1 (enExample) |
| IL (1) | IL207652A0 (enExample) |
| MX (1) | MX2010009131A (enExample) |
| NZ (1) | NZ587348A (enExample) |
| RU (1) | RU2010138603A (enExample) |
| TW (1) | TW200942614A (enExample) |
| WO (1) | WO2009104807A1 (enExample) |
| ZA (1) | ZA201006125B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3533445A1 (en) * | 2009-03-19 | 2019-09-04 | Fate Therapeutics, Inc. | Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same |
| US20100305203A1 (en) * | 2009-05-27 | 2010-12-02 | Sucampo Ag | Method for modulating claudin mediated functions |
| US8569279B2 (en) | 2009-05-27 | 2013-10-29 | Sucampo Ag | Method for modulating claudin mediated functions |
| KR101171912B1 (ko) | 2010-11-29 | 2012-08-07 | 기아자동차주식회사 | 밸브브릿지 일체형 가변 밸브 액츄에이터 |
| PT2785834T (pt) | 2011-12-02 | 2020-11-13 | Fate Therapeutics Inc | Composição de células estaminais melhorada |
| EP2785350B1 (en) | 2011-12-02 | 2018-05-02 | Fate Therapeutics, Inc. | Improved methods of treating ischemia |
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
| US10851412B2 (en) | 2013-03-15 | 2020-12-01 | Fate Therapeutics, Inc. | Cell potency assay for therapeutic potential |
| US20140371304A1 (en) * | 2013-06-13 | 2014-12-18 | Sucampo Ag | Method for suppressing tumorigenicity of stem cells |
| US9918994B2 (en) | 2016-03-04 | 2018-03-20 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for muscle regeneration using prostaglandin E2 |
| JP2019513010A (ja) * | 2016-03-04 | 2019-05-23 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | プロスタグランジンｅ２を用いる、筋再生のための組成物および方法 |
| AU2018280264B2 (en) | 2017-06-09 | 2024-07-11 | Myoforte Therapeutics, Inc. | Compositions and methods for preventing or treating muscle conditions |
| RU2686718C1 (ru) * | 2018-03-12 | 2019-04-30 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Средство, стимулирующее функции мезенхимальных клеток-предшественников in vitro |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166174A (en) * | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
| CA1322749C (en) * | 1987-01-28 | 1993-10-05 | Ryuzo Ueno | Prostaglandins of the d series, and tranquilizers and soporifics containing the same |
| US5221763A (en) * | 1987-04-30 | 1993-06-22 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
| CA2039420C (en) * | 1990-04-04 | 1996-12-10 | Ryuji Ueno | Treatment of cataract with 15-keto-prostaglandin compounds |
| ES2093774T3 (es) * | 1991-03-14 | 1997-01-01 | R Tech Ueno Ltd | Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina. |
| CA2150287C (en) * | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
| US5703108A (en) * | 1996-02-28 | 1997-12-30 | Pfizer Inc. | Bone deposition by certain prostaglandin agonists |
| EP0857718B1 (en) * | 1996-06-10 | 2002-08-14 | Sucampo AG | Endothelin antagonist |
| AU2001239551B8 (en) * | 2000-03-24 | 2005-11-24 | Sucampo Ag | Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof |
| US8202909B2 (en) | 2005-01-27 | 2012-06-19 | Sucampo Ag | Method for treating central nervous system disorders |
| JP4557288B2 (ja) * | 2005-01-28 | 2010-10-06 | アイシン・エィ・ダブリュ株式会社 | 画像認識装置及び画像認識方法、並びにそれを用いた位置特定装置、車両制御装置及びナビゲーション装置 |
| EP1853271B1 (en) * | 2005-03-04 | 2010-12-01 | Sucampo AG | Method and composition for treating peripheral vascular diseases |
| US20060281818A1 (en) | 2005-03-21 | 2006-12-14 | Sucampo Ag, North Carolina State University | Method for treating mucosal disorders |
| WO2007070964A1 (en) | 2005-12-22 | 2007-06-28 | Es Cell International Pte Ltd | Direct differentiation of cardiomyocytes from human embryonic stem cells |
| RU2425876C2 (ru) | 2006-03-24 | 2011-08-10 | Чилдрен'З Медикал Сентер Корпорейшн | Способ модулирования роста гематопоэтических стволовых клеток |
| WO2008073748A1 (en) | 2006-12-08 | 2008-06-19 | University Of Rochester | Expansion of hematopoietic stem cells |
| WO2008108322A2 (en) | 2007-02-27 | 2008-09-12 | Sucampo Ag | Composition and method for protecting mitochondria |
| FI20075417A0 (fi) | 2007-06-05 | 2007-06-05 | Marjo-Riitta Suuronen | Koostumuksia ja menetelmiä alkion kantasolujen kasvatukseen |
-
2009
- 2009-02-18 US US12/388,048 patent/US8871752B2/en not_active Expired - Fee Related
- 2009-02-19 RU RU2010138603/15A patent/RU2010138603A/ru not_active Application Discontinuation
- 2009-02-19 TW TW098105222A patent/TW200942614A/zh unknown
- 2009-02-19 EP EP13178225.2A patent/EP2656845A1/en not_active Withdrawn
- 2009-02-19 KR KR1020107021031A patent/KR20100119803A/ko not_active Ceased
- 2009-02-19 AU AU2009216067A patent/AU2009216067B2/en not_active Ceased
- 2009-02-19 BR BRPI0907831A patent/BRPI0907831A2/pt not_active IP Right Cessation
- 2009-02-19 CN CN200980114702XA patent/CN102014921A/zh active Pending
- 2009-02-19 CA CA2715486A patent/CA2715486A1/en not_active Abandoned
- 2009-02-19 JP JP2010533155A patent/JP2011512323A/ja not_active Ceased
- 2009-02-19 EP EP09712320A patent/EP2303278A1/en not_active Withdrawn
- 2009-02-19 WO PCT/JP2009/053474 patent/WO2009104807A1/en not_active Ceased
- 2009-02-19 NZ NZ587348A patent/NZ587348A/en not_active IP Right Cessation
- 2009-02-19 AR ARP090100582A patent/AR073158A1/es unknown
- 2009-02-19 CN CN201410464976.4A patent/CN104248638A/zh active Pending
- 2009-02-19 MX MX2010009131A patent/MX2010009131A/es not_active Application Discontinuation
-
2010
- 2010-08-17 IL IL207652A patent/IL207652A0/en unknown
- 2010-08-27 ZA ZA2010/06125A patent/ZA201006125B/en unknown
-
2014
- 2014-09-16 US US14/487,153 patent/US20150005381A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009104807A1 (en) | 2009-08-27 |
| MX2010009131A (es) | 2010-12-06 |
| CN102014921A (zh) | 2011-04-13 |
| BRPI0907831A2 (pt) | 2017-04-11 |
| IL207652A0 (en) | 2010-12-30 |
| CA2715486A1 (en) | 2009-08-27 |
| KR20100119803A (ko) | 2010-11-10 |
| TW200942614A (en) | 2009-10-16 |
| NZ587348A (en) | 2012-04-27 |
| JP2011512323A (ja) | 2011-04-21 |
| EP2656845A1 (en) | 2013-10-30 |
| US20150005381A1 (en) | 2015-01-01 |
| AU2009216067A1 (en) | 2009-08-27 |
| AR073158A1 (es) | 2010-10-20 |
| US20090209643A1 (en) | 2009-08-20 |
| CN104248638A (zh) | 2014-12-31 |
| ZA201006125B (en) | 2011-05-25 |
| US8871752B2 (en) | 2014-10-28 |
| EP2303278A1 (en) | 2011-04-06 |
| AU2009216067B2 (en) | 2014-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010138603A (ru) | Композиция для модуляции роста стволовых клеток простагландинами | |
| CA2600331A1 (en) | Use of 11-deoxy-prostaglandin for treating peripheral vascular diseases | |
| RU2420291C3 (ru) | Состав в мягкой желатиновой капсуле | |
| RU2012119778A (ru) | Водная композиция | |
| JP2011512323A5 (enExample) | ||
| EP2446024A1 (en) | Mesenchymal stem cells grown under hypoxic conditions: compositions, methods and uses therefor | |
| JPWO2013100080A1 (ja) | ｉＰＳ細胞の腫瘍化を抑制することが可能な分化誘導方法 | |
| RU2013151166A (ru) | Способ модуляции активности цитокинов | |
| Pall et al. | New insights into the cellular makeup and progenitor potential of palatal connective tissues | |
| Zhu et al. | Evaluating the efficacy of dedifferentiated fat cells (DFATs) vs adipose-derived stem cells (ASCs) in enhancing the viability of fat grafts | |
| RU2007132081A (ru) | Способ и композиция для лечения заболеваний центральной нервной системы | |
| RU2013135403A (ru) | Фармацевтическая композиция, содержащая 11-дезокси-простагландиновое соединение и способ стабилизации этого соединения | |
| RU2011146128A (ru) | Способ и композиция для лечения дегенерации желтого пятна | |
| CA2404767A1 (en) | Bile secretion promoting composition containing a 15-keto prostaglandin | |
| JP2008528440A5 (enExample) | ||
| Fang et al. | Human Adipose Tissue–Derived Adult Stem Cells Can Lead to Multiorgan Engraftment | |
| Sa’dyah et al. | Suppression of transforming growth factor-β by mesenchymal stem-cells accelerates liver regeneration in liver fibrosis animal model | |
| RU2011153196A (ru) | Фармацевтическая композиция, содержащая производные простагландинов, для применения в модулировании опосредованных клаудином функций и лечении дерматологических нарушений | |
| AR087468A1 (es) | Metodo para tratar la esquizofrenia | |
| Peter et al. | CD45/CD11b positive subsets of adult lung anchorage‐independent cells harness epithelial stem cells in culture | |
| JP2016528165A5 (enExample) | ||
| JP2014527048A5 (enExample) | ||
| JP2004521960A5 (enExample) | ||
| US20140371304A1 (en) | Method for suppressing tumorigenicity of stem cells | |
| JP2005519978A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150515 |